Agenus Inc (AGEN) 5.65 $AGEN Antigenics Up 33.7% Since

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Agenus Inc (AGEN) 5.65 $AGEN

Antigenics Up 33.7% Since SmarTrend Uptrend Call (AGEN)
Comtex SmarTrend(R) - Fri Jul 29, 1:21PM CDT
SmarTrend identified an Uptrend for Antigenics (NASDAQ:AGEN) on May 31st, 2016 at $4.18. In approximately 2 months, Antigenics has returned 33.65% as of today's recent price of $5.58.
AGEN: 5.65 (+0.10)

Agenus (AGEN) Posts Narrower than Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Fri Jul 29, 8:47AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 24 cents per share, narrower than the Zacks Consensus Estimate of a loss of 34 cents.
AGEN: 5.65 (+0.10), ANIP: 61.06 (+0.46), MRK: 58.66 (unch), NKTR: 17.76 (+0.47)

Agenus (AGEN) Reports Narrower-than-Expected Q2 Loss
Zacks Equity Research - Zacks Investment Research - Thu Jul 28, 9:43AM CDT
Agenus (AGEN) reported a loss of 24 cents in second-quarter of 2016, lower than the Zacks Consensus Estimate of 34 cents.
AGEN: 5.65 (+0.10)

Agenus Reports Second Quarter 2016 Financial Results and Operational Progress
BusinessWire - Thu Jul 28, 7:49AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company developing antibodies, including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.
AGEN: 5.65 (+0.10)

Watch for Drug Stocks Earnings on Jul 28: BMY, CELG & More
Zacks Equity Research - Zacks Investment Research - Wed Jul 27, 8:47AM CDT
How will drug stocks Bristol-Myers, Celgene and others perform when they report Q2 results on Jul 28, before the opening bell?
AGEN: 5.65 (+0.10), BIIB: 304.00 (+2.17), ABT: 45.29 (unch), JNJ: 125.48 (+0.08), GILD: 80.69 (+0.23), ALXN: 133.50 (+4.90), ARIA: 9.68 (-0.03), BMY: 76.50 (+0.31), CELG: 114.80 (+0.11), NVS: 83.28 (+0.21)

Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors
BusinessWire - Wed Jun 22, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that the first patient has been dosed in a Phase 1/2 clinical trial of the anti-GITR agonist antibody INCAGN1876. The trial is being conducted by, and in collaboration with, Incyte Corporation.
AGEN: 5.65 (+0.10)

Agenus to Present at the 2016 JMP Securities Life Sciences Conference
BusinessWire - Wed Jun 15, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Robert B. Stein, M.D., Ph.D., President, Research & Development, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22nd at 3:30 p.m. ET. The conference will take place at the St. Regis New York in New York City.
AGEN: 5.65 (+0.10)

Agenus Announces Lead Product Candidate Selection in its Collaboration with Merck
BusinessWire - Thu Jun 09, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators (CPMs) and cancer vaccines, today announced the selection of a lead product candidate under its license and research collaboration with Merck. Merck, known as MSD outside the United States and Canada, has selected a lead antibody candidate and several backup antibodies, discovered by Agenus, to an undisclosed Merck checkpoint target. Based on this milestone and under the terms of the agreement, Agenus received a $2 million milestone payment from Merck.
AGEN: 5.65 (+0.10), MRK: 58.66 (unch)

Agenus to Webcast Annual Meeting of Stockholders
BusinessWire - Wed Jun 08, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, invites investors and the general public to its Annual Meeting of Stockholders to begin at 5:00 p.m. ET on Tuesday, June 14, 2016. The meeting will be held at the Company's headquarters located at 3 Forbes Road, Lexington, MA 02421. Registration for attendees starts at 4:30 p.m. ET.
AGEN: 5.65 (+0.10)

Agenus to Present at the Jefferies 2016 Healthcare Conference
BusinessWire - Thu Jun 02, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced that Garo H. Armen, Ph.D., Chairman and CEO, and Robert B. Stein, M.D., Ph.D., President, Research & Development, will present a corporate overview at the Jefferies 2016 Healthcare Conference in New York City on Thursday, June 9th at 9:30am ET.
AGEN: 5.65 (+0.10)

Agenus Appoints Ulf Wiinberg to Board of Directors
BusinessWire - Thu May 19, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing antibodies including checkpoint inhibitors and other checkpoint modulators, and cancer vaccines, today announced the appointment of Ulf Wiinberg to the Company's Board of Directors. Ulf has more than 30 years of pharmaceutical experience and currently serves on the boards of multiple global drug development companies.
AGEN: 5.65 (+0.10)

Agenus' (AGEN) Q1 Loss Wider than Expected, Revenue Miss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:41AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 37 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents.
AGEN: 5.65 (+0.10), EBS: 30.97 (-2.42), AEGR: 1.47 (+0.03), GSK: 45.67 (+0.42)

Agenus (AGEN) Reports Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 9:41AM CDT
Agenus (AGEN) reported wider-than-expected first quarter loss of 37 cents per share.
AGEN: 5.65 (+0.10)

Agenus reports 1Q loss
Automated Insights - Thu Apr 28, 7:56AM CDT
LEXINGTON, Mass. (AP) _ Agenus Inc. (AGEN) on Thursday reported a loss of $31.8 million in its first quarter.
AGEN: 5.65 (+0.10)

Agenus Reports First Quarter 2016 Financial Results and Operational Progress
BusinessWire - Thu Apr 28, 7:50AM CDT
Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.
AGEN: 5.65 (+0.10)

Drug Stocks' Earnings Previews: KERX, BXLT, BMRN, AGEN, IMGN
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 11:10AM CDT
With the first-quarter earnings season in full swing, investors are possibly seeing a ray of hope, as results reported so far have not been as dismal as expected.
AGEN: 5.65 (+0.10), BIIB: 304.00 (+2.17), JNJ: 125.48 (+0.08), BMRN: 100.25 (+0.83), SHPG: 201.65 (+7.65), IMGN: 2.96 (+0.18), BXLT: 46.02 (-0.18), KERX: 4.61 (-0.11), NVS: 83.28 (+0.21)

Agenus Commences Phase 1 Clinical Trial of its CTLA-4 Checkpoint Antibody to Treat Solid Tumors
BusinessWire - Wed Apr 27, 7:50AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint antibodies and cancer vaccines, today announced that the first patient has been dosed in the company's Phase 1 clinical trial of AGEN1884, an anti-CTLA-4 checkpoint (CPM) antibody. The open-label, multicenter trial in patients with advanced or refractory cancer is designed to evaluate the safety of AGEN1884 and determine the estimated maximum tolerated dose.
AGEN: 5.65 (+0.10)

Agenus to Report First Quarter 2016 Financial Results on April 28, 2016; Conference Call to Follow
BusinessWire - Thu Apr 21, 6:00AM CDT
Agenus Inc. (NASDAQ: AGEN) will release its first quarter 2016 financial results before the market opens on Thursday, April 28, 2016. Agenus executives will host a conference call at 11 a.m. Eastern Time the same day.
AGEN: 5.65 (+0.10)

Agenus Presents Posters on Checkpoint Antibody Product Candidates at the American Association for Cancer Research (AACR) 2016 Annual Meeting
BusinessWire - Mon Apr 18, 9:30AM CDT
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company developing checkpoint modulator antibodies and cancer vaccines, today announced that three abstracts on the Company's checkpoint modulator product candidates were accepted for poster presentations at the American Association for Cancer Research (AACR) 2016 Annual Meeting. The conference is taking place in New Orleans from April 16-20, 2016.
AGEN: 5.65 (+0.10)

The Last Time This Company Made A FDA Submission It Ran 2,100%-- Here's Why You Should Be Looking At It Right Now
ACCESSWIRE - Wed Mar 30, 6:00AM CDT
WINDSOR, ON / ACCESSWIRE / March 30, 2016 / The Wealthy Biotech Trader (or "WBT", an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known, biotech, pharma and medical device stocks making news and subsequent market moves, would like to highlight that the maximum gains are made by investors who seek out promising pharma companies before their filing of FDA approval.
AGEN: 5.65 (+0.10), ARGS: 5.31 (+0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 152

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Cargo Drones to Skyrocket with $9.14B Value by 2031

Updated Category News Views 121

Riding the Drone Wave I tell you what, folks, the whole business of cargo drones is getting frickin' interesting. These flying gizmos, once dismissed as science fiction, are now barging their way into logistics discussions like an uninvited guest who's too worthwhile to ignore. MarketsandMarkets™ reckons this market's about to smash through the $9 billion ceiling by...

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 28

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Keiki Smiles Boosts Pediatric Dental Care in Waipahu

Updated Category News Views 83

A Neighborhood Dentists' Big Move: Keiki Smiles Expands in Waipahu Well, if there's one thing the dentists of Waipahu know how to do, it's adapt and grow. Keiki Smiles of Leeward, a trusted name in pediatric dentistry, just set up shop at a fresh location. The move marks a new chapter for this community staple, and honestly, it's miles more than just a longer lease and a...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 30

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Caregiving's Financial Impact on Women: Insights from Cinergy

Updated Category News Views 106

Women Caregivers Face Financial Crossroads When it comes down to it, caregiving is one heck of a responsibility, particularly for women. It's about the sacrifices they make, not just in time but in financial security, too. Step away from a job to care for someone, and it's a dicey game you're playing with future income. The Cost of Generosity: Financial Impacts Cindy...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 22

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 81

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading
Christian Faith: Navigating Spiritual Pitfalls Wisely

Updated Category News Views 111

Taking a Deep Look at Christian Faith If you think faith is as simple as saying a few prayers and checking church attendance off the list, well, think again. G. Joseph Johnson, in his thought-provoking tome "Roads, Ditches, Traps, and Snares," believes that faith is a journey filled with twists, turns, and yes, a few traps. This book is a sort of roadmap for Christians,...

Continue Reading

Top 5 Most Recently Viewed Articles

Investigation Launched for SelectQuote, Inc. Shareholders

Updated Category News Views 231

Rosen Law Firm Investigates SelectQuote, Inc. Securities Claims The Rosen Law Firm has recently announced an investigation focusing on SelectQuote, Inc. (NYSE: SLQT) due to potential securities claims that may affect shareholders. The firm is dedicated to upholding investor rights and protecting shareholders from misleading information that might influence stock...

Continue Reading
Indonesia's IDX Composite Index Experiences Minor Decline

Updated Category News Views 239

Well, let’s cut to the chase. Indonesia's stock market is feeling a bit queasy lately. The IDX Composite Index slipped by 0.18%, taking a hit thanks to major sectors like Financials, Infrastructure, and Agriculture showing significant losses. This isn’t just some random shuffle; these sectors often serve as economic bellwethers that reflect broader trends in the...

Continue Reading
Trade Tensions Impact Qualcomm Stock Performance Today

Updated Category News Views 126

Trade Tensions Impact Qualcomm Shares Qualcomm Inc (NASDAQ: QCOM) is experiencing a decline in its share price, attributed to rising trade tensions. Reports indicate that the U.S. government is preparing to implement restrictions on AI chip shipments to certain Southeast Asian countries, primarily Malaysia and Thailand, due to ongoing concerns regarding China. New Export...

Continue Reading
Historic $100 Million Donation to Improve Pediatric Mental Health

Updated Category News Views 184

Transforming Pediatric Behavioral Health BOSTON — A groundbreaking gift of $100 million from Rob and Karen Hale has been announced by Boston Children's Hospital. This donation marks the largest in the hospital's storied history and is set to revolutionize pediatric behavioral health care. The Hale family's incredible generosity is aimed at reimagining how mental and...

Continue Reading
Mark Carney Takes Charge: Canada's Bold Steps to Trade Victory

Updated Category News Views 414

Mark Carney: Canada's New Prime Minister Mark Carney has emerged victorious in the leadership race of the Liberal Party, succeeding Justin Trudeau as Canada’s prime minister. With a commanding win, he pledged to confront U.S. President Donald Trump head-on, especially regarding increasing trade tensions. A Strong Start in Leadership In a remarkable demonstration of...

Continue Reading